Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

28 juin 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial

MADISON, Wis., June 28, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
07 juin 2018 08h30 HE | Source: Cellectar Biosciences, Inc.

Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131

MADISON, Wis., June 07, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
06 juin 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma

MADISON, Wis., June 06, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
11 mai 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results

MADISON, Wis., May 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
09 mai 2018 14h28 HE | Source: Cellectar Biosciences, Inc.

Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma

MADISON, Wis., May 09, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
02 mai 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Receives Rare Pediatric Disease Designation for CLR 131 to Treat Neuroblastoma

MADISON, Wis., May 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
17 avr. 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating Efficacy of Fractionated Injections of CLR 131 in Multiple Myeloma

MADISON, Wis., April 17, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
16 avr. 2018 08h05 HE | Source: Cellectar Biosciences, Inc.

Cellectar Presents Preclinical Data at AACR Annual Meeting Demonstrating the Ability of its PDCs to Selectively Target a Broad Range of Tumor Cells

MADISON, Wis., April 16, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
16 avr. 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of Cellectar’s CLR 131 in Head and Neck Cancer Presented at AACR Annual Meeting

MADISON, Wis., April 16, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
04 avr. 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer

MADISON, Wis., April 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...

Page précédente

Page suivante